Aptevo Therapeutics (APVO) Coverage Initiated at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a note issued to investors on Monday, MarketBeat.com reports. The firm set a “buy” rating and a $14.00 price target on the biotechnology company’s stock. LADENBURG THALM/SH SH’s price target would indicate a potential upside of 273.33% from the company’s current price.

Several other equities analysts have also commented on the company. ValuEngine upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, August 13th. Zacks Investment Research lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $11.00 price target on shares of Aptevo Therapeutics in a research note on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $10.69.

Shares of Aptevo Therapeutics stock opened at $3.75 on Monday. The firm has a market cap of $82.29 million, a PE ratio of -2.45 and a beta of 2.27. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.50 and a current ratio of 3.66. Aptevo Therapeutics has a 12 month low of $2.54 and a 12 month high of $6.35.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07. The firm had revenue of $6.83 million for the quarter, compared to analyst estimates of $4.17 million. Aptevo Therapeutics had a negative return on equity of 45.53% and a net margin of 74.01%. Sell-side analysts predict that Aptevo Therapeutics will post -2.41 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. Northern Trust Corp increased its stake in shares of Aptevo Therapeutics by 21.2% during the second quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 12,299 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Aptevo Therapeutics during the second quarter valued at $148,000. Acadian Asset Management LLC increased its stake in shares of Aptevo Therapeutics by 20.2% during the third quarter. Acadian Asset Management LLC now owns 441,765 shares of the biotechnology company’s stock valued at $2,244,000 after buying an additional 74,256 shares during the period. EAM Investors LLC purchased a new position in shares of Aptevo Therapeutics during the second quarter valued at $552,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Aptevo Therapeutics by 11.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,219,852 shares of the biotechnology company’s stock valued at $3,989,000 after buying an additional 123,236 shares during the period. Hedge funds and other institutional investors own 33.09% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Read More: What is Cost of Debt?

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply